KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin (2016 - 2025)

Historic Net Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 13.01%.

  • TherapeuticsMD's Net Margin rose 206900.0% to 13.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.19%, marking a year-over-year decrease of 326000.0%. This contributed to the annual value of 7.44% for FY2024, which is 2055200.0% up from last year.
  • Per TherapeuticsMD's latest filing, its Net Margin stood at 13.01% for Q3 2025, which was up 206900.0% from 0.63% recorded in Q2 2025.
  • TherapeuticsMD's Net Margin's 5-year high stood at 36538.51% during Q2 2022, with a 5-year trough of 4481.44% in Q1 2022.
  • Over the past 5 years, TherapeuticsMD's median Net Margin value was 6.0% (recorded in 2024), while the average stood at 1329.46%.
  • Over the last 5 years, TherapeuticsMD's Net Margin had its largest YoY gain of 367239400bps in 2022, and its largest YoY loss of -42832000bps in 2022.
  • TherapeuticsMD's Net Margin (Quarter) stood at 268.5% in 2021, then plummeted by -84bps to 42.66% in 2022, then surged by 207bps to 131.08% in 2023, then crashed by -84bps to 20.69% in 2024, then crashed by -37bps to 13.01% in 2025.
  • Its last three reported values are 13.01% in Q3 2025, 0.63% for Q2 2025, and 4.33% during Q1 2025.